Oncology

Official Twitter account of @PracticeUpdate Oncology. Includes commentaries, journal scans, conference coverage, news items & more. Part of Elsevier.

[Oncology @PracUpOnc]

Clinicopathologic Characteristics and Prognostic Impact of Atypical EGFR Mutations in Patients With Completely Resected Lung Adenocarcinoma
https://t.co/5PvVl2tYri #lcsm #lungcancer

[Oncology @PracUpOnc]

First-line Nivolumab Plus Ipilimumab With Chemotherapy vs Chemotherapy Alone in Patients With Metastatic NSCLC With Brain Metastases or Select Somatic Mutations
https://t.co/WzHSRjxpUN #lcsm #lungcancer

[Oncology @PracUpOnc]

Long-Term Outcomes Following Pembrolizumab vs Chemotherapy as First-Line Therapy in Patients With NSCLC With PD-L1 Tumor Proportion Score ≥1%
https://t.co/Ur6zQOfabV #lcsm #lungcancer

[Oncology @PracUpOnc]

Prognostic Scores Including Peripheral Blood–Derived Inflammatory Indices in Patients With Advanced NSCLC Treated With Immune Checkpoint Inhibitors
https://t.co/dQFNdpS3Ot #lcsm #lungcancer

[Oncology @PracUpOnc]

Durvalumab With or Without Tremelimumab Plus Chemotherapy as First-Line Therapy for Metastatic NSCLC
https://t.co/T18Mo4I0Qx #lcsm #lungcancer

[Oncology @PracUpOnc]

Long-Term Survival Outcomes With Nivolumab Plus Ipilimumab vs Chemotherapy as First-Line Treatment for Metastatic NSCLC
https://t.co/qkATrF8OSR #lcsm #lungcancer

[Oncology @PracUpOnc]

Practical Considerations for the Use of Circulating Tumor DNA in the Treatment of Patients With Cancer
https://t.co/KwOm7Ramf3 #lcsm #lungcancer

[Oncology @PracUpOnc]

ESMO Clinical Practice Guideline for the Diagnosis and Management of Toxicities From Immunotherapy
https://t.co/PcCCWlMO1c #lcsm #lungcancer

[Oncology @PracUpOnc]

Resected Non-Small Cell Lung Cancer: How Far to Go With Molecular Testing?
https://t.co/TyOF7GlLbB #lcsm #lungcancer

[Oncology @PracUpOnc]

Osimertinib Plus Savolitinib to Overcome Acquired MET-Mediated Resistance in Patients With EGFR–Mutated MET-Amplified NSCLC
https://t.co/YJqHhg9uJI #lcsm #lungcancer

[Oncology @PracUpOnc]

Treatment Characteristics and Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy
https://t.co/Ko4ZUHg6QX #lcsm #lungcancer

[Oncology @PracUpOnc]

Long-Term Outcomes Following Postoperative SRS vs WBRT for Resected Brain Metastasis
https://t.co/CU2R5olsOd #lcsm #lungcancer

[Oncology @PracUpOnc]

5 Tips for Staying Updated in Medical Literature
https://t.co/z93qMtKmYv #lcsm #lungcancer

[Oncology @PracUpOnc]

Aprepitant vs Desloratadine for EGFR-TKI–Induced Pruritus in Patients With NSCLC
https://t.co/Nw2Lz4XppO #lcsm #lungcancer

[Oncology @PracUpOnc]

Many Women Lack Information on Breast Reconstruction After Mastectomy
https://t.co/eDpXLaWJ4G #oncology

[Oncology @PracUpOnc]

Adjuvant Capecitabine Following Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
https://t.co/0YiW4xDNv3 #oncology

[Oncology @PracUpOnc]

Predicting Richter's Transformation in Patients With CLL Receiving Ibrutinib
https://t.co/ez3OTvmhq9 #oncology

[Oncology @PracUpOnc]

Iberdomide Plus Dexamethasone for Heavily Pretreated Late-Line Relapsed/Refractory Multiple Myeloma
https://t.co/kVnxBk3ufd #oncology

[Oncology @PracUpOnc]

Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Cancer
https://t.co/mGkAZNssza #oncology

[Oncology @PracUpOnc]

Robot-Assisted Partial Nephrectomy vs Percutaneous Thermal Ablation in Patients With a Solitary Kidney With RCC cT1
https://t.co/WcOiYq8BSQ #RCC #kcsm